Evidence-Based Complementary and Alternative Medicine
Volume 2016 (2016), Article ID 5616905, 7 pages
http://dx.doi.org/10.1155/2016/5616905

Research Article

Effect of Aurantii Fructus Immaturus Flavonoid on the Contraction of Isolated Gastric Smooth Muscle Strips in Rats

Zhenyu Wu, Shengsheng Zhang, Peicai Li, Xiaofang Lu, Jiajia Wang, Luqing Zhao, and Yueqi Wang

Digestive Disease Center, Beijing Hospital of Traditional Chinese Medicine Affiliated to Capital Medical University, Beijing 100010, China

Received 15 February 2016; Revised 16 May 2016; Accepted 30 May 2016

Academic Editor: Jiande D. Z. Chen

Copyright © 2016 Zhenyu Wu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract.

This study was designed to investigate the effect of Aurantii fructus immaturus flavonoid (AFIF) on the contraction of isolated gastric smooth muscle in rats and explore its underlying mechanisms. Isolated antral longitudinal smooth muscle strip (ALSMS) and pyloric circular smooth muscle strip (PCSMS) of rats were suspended in tissue chambers. The responses of ALSMS and PCSMS to administration of AFIF were observed. Cyclic guanosine monophosphate (cGMP) and protein kinase G (PKG) levels of PCSMS were measured by ELISA kits. In this study, AFIF showed no significant effect on ALSMS contraction, but it dose-dependently reduced the mean contraction amplitude of PCSMS. When the concentration of AFIF reached 3000 g/mL, 6000 g/mL, and 10000 g/mL, its inhibitory effect on PCSMS contraction was significant. This effect of AFIF was weakened in Ca²⁺-rich environment. And N-nitro-L-arginine methyl (L-NAME), the inhibitor of nitric oxide synthase (NOS), significantly inhibited AFIF’s action in comparison with control (). After incubation with AFIF for 30 min, levels of cGMP and PKG in PCSMS were significantly increased compared with control (). Our results suggest that AFIF has a dose-dependent diastolic effect on PCSMS in rats, which may be related to the regulatory pathway of NO/cGMP/PKG/Ca²⁺.

1. Introduction

Functional dyspepsia (FD) is a disease defined as persistent or recurrent postprandial upper abdominal discomfort and epigastric pain in the absence of any organic, systemic, or metabolic diseases in the Rome criteria [1]. According to a systemic review, FD has a high prevalence of 11.5%~14.5% all over the world [2], and it markedly reduces patients’ quality of life [3, 4]. Gastric emptying dysfunction is recognized as one of the pathogenic factors of FD and causes the main clinical symptoms of this disease [5]. Unfortunately, existing prokinetic drugs are still not satisfactory to promote the symptoms of FD.

Recently, therapeutic effects of Chinese herbals and their extracts on FD have been paid a close attention [6]. Aurantii fructus immaturus (AFI), the dry fruit of Citrus aurantium L. and Citrus sinensis Osbeck, is one of the main Chinese herbals to treat gastrointestinal disorders. Previous study has shown that AFI contributes to the treatment of FD [7]. As the major effective constituent of AFI [8], Aurantii fructus immaturus flavonoid (AFIF) can promote gastric empting process in FD rats [9]. However, the mechanism of the therapeutic effect of AFIF is not yet clear, and AFIF’s action on isolated gastric muscle strips has not been reported.

As we know, antrum and pylorus are two important functional units in gastric emptying process. The normal conduct of gastric emptying process depends on the contraction of antral muscle, the relaxing of pyloric muscle, and the coordination of these two functional units. And the pathway of NO/cGMP/PKG contributes to the regulation of gastric muscle contraction by regulating Ca²⁺ influx process.

In this paper, we studied AFIF’s action on isolated antral muscle strips and pyloric muscle strips in rats to investigate whether it promotes antral muscle contraction or weakens pyloric muscle contraction. To explore the connection between AFIF’s action and the influx of extracellular Ca²⁺, we studied AFIF’s action in different Ca²⁺ environment. To explore the mechanisms of AFIF’s action based on NO/cGMP/PKG pathway, we studied the effect of L-NAME on AFIF’s action and measured the cGMP and PKG levels of muscle strips after AFIF incubation.

2. Materials

2.1. Animals

Male Sprague-Dawley rats, obtained from the Vital River Laboratories, China, and weighing 290–310 g, were used. The animals were accommodated in suitable conditions (at 22°C and fed ad libitum). The study was conducted in accordance with the principles of the National Institute of Health Guide for the Care and Use of Laboratory Animals, and permission was received from the local ethics committee of Beijing Hospital of Traditional Chinese Medicine.

2.2. Drugs and Reagents

AFIF (batch number: 20140305, made and identified by Jiangxi Qingfeng Pharmaceutical Co., Ltd. for Drug Control) was dispensed into different concentrations with Krebs solution, respectively. The following reagents were used: acetylcholine chloride (batch number: A6625, Sigma-Aldrich Co. LLC), neostigmine bromide (batch number: N2001, Sigma-Aldrich Co. LLC), atropine sulfate (batch number: 1306281, Beijing Hospital of Traditional Chinese Medicine), and -nitro-L-arginine methyl (L-NAME, batch number: N5751, Sigma-Aldrich Co. LLC). Krebs solution had the following composition in mmol/L: NaCl 120.6, KCl 5.9, NaH₂PO₄ 1.2, MgCl₂ 1.2, NaHCO₃ 15.4, CaCl₂ 2.5, and C₆H₁₂O₆ 11.5. Rat cyclic guanosine monophosphate (cGMP) ELISA kit (batch number: KGE003, R&D systems) and rat protein kinase G (PKG) ELISA kit (batch number: EY-(Ela)-2763, Shanghai Yi Yan Biological Technology Co., Ltd., China) were used to measure the levels of cGMP and PKG.

2.3. Apparatus

CH-1015 super thermostatic bath was from Shanghai Yueping Scientific Instrument Co., Ltd., China. Flowing apparatus was from AD Instruments, Australia: MLT 02021D external isometric force transducer, PL 3508-0028 four-channel recorder, ML 0146/C-V Panlab Four-Chamber Organ Bath, ML110 Powerlab amplifier, and PowerLab/4SP data processing and analysis system.

3. Methods

3.1. Tissue Preparation

All rats were fasted with free access to water for 20 hours. Each rat was hit to lose consciousness and the whole stomach was removed. The stomach was opened along greater curvature and rinsed with Krebs solution. Muscle strips (8 mm × 2 mm) cut parallel to longitudinal fibers of the antrum were named as antral longitudinal smooth muscle strips (ALSMS), and muscle strips (8 mm × 2 mm) cut parallel to circular fibers of the pylorus were named as pyloric circular smooth muscle strips (PCSMS) [10]. Each strip with the mucosa removed was suspended in a tissue chamber containing 15 mL Krebs solution, constantly warmed by circulating water jacked at 37°C and supplied with a mixed gas of 95% O₂ and 5% CO₂. One end of each strip was fixed to a hook on the bottom of the chamber while the other end was connected by a thread to an external isometric force transducer (MLT 02021D) at the top. Each strip was subjected to 1 g load tension and washed with 15 mL Krebs solution every 15 minutes. The contractions of strips were simultaneously recorded by PL 3508-0028 four-channel recorder and analyzed by PowerLab/4SP data processing and analysis system. After equilibrating for 1 h to get a stable baseline, whose mean contraction amplitude was recognized as 100%, 5 μL of normal saline (NS) was added as control (AFIF concentration was 0 μg/mL). Tissue preparation was done before each experiment.

3.2. Experiments

3.2.1. AFIF’s Effect on the Contraction of Gastric Smooth Muscle Strips

AFIF was added to the bath continuously at intervals of 5 min, so that the cumulative concentration of AFIF in each chamber reached 3 μg/mL, 30 μg/mL, 300 μg/mL, 3000 μg/mL, 6000 μg/mL, and 10000 μg/mL step by step; the contraction amplitude and contractile frequency of each strip were observed.

3.2.2. Effect of Extracellular Ca²⁺ Concentration on AFIF’s Action

15 mL of Ca²⁺-lack Krebs solution (Ca²⁺ concentration was 1.25 mmol/L) or Ca²⁺-rich Krebs solution (Ca²⁺ concentration was 5 mmol/L) was put into each chamber instead of normal Krebs solution (Ca²⁺ concentration was 2.5 mmol/L). Then AFIF was added to each bath continuously at intervals of 5 min, so that the cumulative concentration of AFIF in each chamber reached 3 μg/mL, 30 μg/mL, 300 μg/mL, 3000 μg/mL, 6000 μg/mL, and 10000 μg/mL. The PCSMS contraction amplitude and contractile frequency were observed.

3.2.3. AFIF’s Action on Abnormal Contraction of Gastric Muscle Strips

Acetylcholine chloride (0.35 μmol/L), neostigmine (1 μmol/L), or atropine (1 μmol/L) was added to the bath, respectively, to induce the abnormal contraction of PCSMS before AFIF administration. Then AFIF was added to each bath continuously at intervals of 5 min, so that the cumulative concentration of AFIF in each chamber reached 3 μg/mL, 30 μg/mL, 300 μg/mL, 3000 μg/mL, 6000 μg/mL, and 10000 μg/mL. The PCSMS contraction amplitude and contractile frequency were observed.

3.2.4. Effect of L-NAME on AFIF’s Action

Strips were incubated with L-NAME (10⁻⁴ mol/L) for 20 min before AFIF administration. Then AFIF was added to each bath continuously at intervals of 5 min, so that the cumulative concentration of AFIF in each chamber reached 3000 μg/mL, 6000 μg/mL, and 10000 μg/mL. The contraction amplitude of each PCSMS was observed.

3.2.5. AFIF’s Effect on cGMP and PKG Levels of Gastric Muscle Strips

AFIF (6000 μg/mL) or NS was added to each chamber containing PCSMS after the incubation for 30 min. Then cGMP and PKG levels of these PCSMS were measured. The testing procedures were carried out according to the instructions of ELISA kits.

3.3. Statistical Analysis

All experimental data were analyzed with one-way analysis of variance or independent -test using SPSS 20.0 software (SPSS, Chicago, IL, USA) and expressed as mean ± SD. was considered statistically significant.

4. Results

4.1. AFIF Showed No Significant Effect on the Contraction of ALSMS

Administration of AFIF affects neither the mean contraction amplitude (Figures 1 and 2) nor the mean contractile frequency (Table 1 and Figure 2) of ALSMS.

Table 1: AFIF’s action on the mean contractile frequency of ALSMS (mean ± SD).

Administration

Mean contractile frequency
(beat per minute, BPM)

NS (control)
9
6.26 ± 0.60

AFIF, 3 μg/mL
9
6.39 ± 0.97

AFIF, 30 μg/mL
9
6.03 ± 0.49

AFIF, 300 μg/mL
9
5.88 ± 0.75

AFIF, 3000 μg/mL
9
5.96 ± 1.23

AFIF, 6000 μg/mL
9
5.69 ± 0.81

AFIF, 10000 μg/mL
9
5.46 ± 0.88

Figure 1: AFIF’s action on the mean contraction amplitude of ALSMS. . The administration of AFIF (3 μg/mL, 30 μg/mL, 300 μg/mL, 3000 μg/mL, 6000 μg/mL, and 10000 μg/mL) did not change the mean contraction amplitude of ALSMS significantly compared with control.

Figure 2: Effect of AFIF on spontaneous contraction of ALSMS recorded by PL 3508-0028 four-channel recorder. AFIF showed no significant influence on ALSMS contraction. Neither the mean contraction amplitude nor the mean contractile frequency of ALSMS changed significantly.

4.2. AFIF Had a Concentration-Dependent Inhibitory Action on the Mean Contraction Amplitude of PCSMS, Which Was Negatively Correlated with Ca²⁺ Concentration

The mean contraction amplitude of PCSMS was decreased by AFIF treatment compared with control. This effect of AFIF was concentration-dependent, which became significant when the concentration of AFIF reached 3000 μg/mL, 6000 μg/mL, and 10000 μg/mL (, ) (Table 2 and Figure 4). This diastolic effect of AFIF on PCSMS was most obvious in Ca²⁺-lack environment, and high Ca²⁺ concentration significantly weakened AFIF’s action () (Figures 3 and 4).

Table 2: AFIF concentration dependently reduced the mean contraction amplitude of PCSMS in different Ca²⁺ environment (mean ± SD).

Administration

Mean contraction amplitude (%)

Ca²⁺-lack
Ca²⁺-normal
Ca²⁺-rich

NS (control)
10
100.03 ± 3.40
101.81 ± 3.35
97.38 ± 7.35

AFIF, 3 μg/mL
10
98.06 ± 4.97
97.60 ± 2.92
98.26 ± 6.47

AFIF, 30 μg/mL
10
95.04 ± 11.34
95.39 ± 7.71
93.92 ± 5.16

AFIF, 300 μg/mL
10
84.47 ± 19.37
82.88 ± 19.89
81.85 ± 10.32

AFIF, 3000 μg/mL
10
59.96 ± 22.09
52.60 ± 17.82
70.95 ± 22.02

AFIF, 6000 μg/mL
10
34.15 ± 31.03
40.58 ± 18.29
47.45 ± 17.39

AFIF, 10000 μg/mL
10
3.96 ± 9.00
24.31 ± 16.90
34.78 ± 16.33

⁢ and versus control.

Figure 3: AFIF’s action on PCSMS contraction amplitude is negatively correlated with Ca²⁺ concentration. , versus Ca²⁺-normal environment. AFIF’s action on PCSMS was most obvious in low Ca²⁺ environment, and the high concentration of Ca²⁺ weakened the diastolic effect of AFIF on PCSMS. When AFIF concentration reached 10000 μg/mL, the PCSMS contraction amplitude in low Ca²⁺ environment was significantly lower than Ca²⁺-normal environment (), while the PCSMS contraction amplitude in high Ca²⁺ environment was significantly higher compared with the Ca²⁺-normal environment ().

Figure 4: Effect of AFIF on spontaneous contraction of PCSMS in different Ca²⁺ environment recorded by PL 3508-0028 four-channel recorder. Low concentration (below 3000 μg/mL) of AFIF had no influence on PCSMS contraction. When the concentration of AFIF reached 3000 μg/mL, 6000 μg/mL, and 10000 μg/mL, AFIF decreased the mean contraction amplitude of PCSMS clearly. The diastolic effect of AFIF on PCSMS was most obvious in Ca²⁺-lack environment, and high Ca²⁺ concentration clearly weakened AFIF’s action.

4.3. AFIF (10000 μg/mL) Showed an Inhibitory Action on the Mean Contractile Frequency of PCSMS

AFIF showed a concentration-dependent inhibitory action on the mean contractile frequency of PCSMS, but it is significant only when the concentration of AFIF reached 10000 μg/mL (Table 3).

Table 3: AFIF’s action on the mean contractile frequency of PCSMS (mean ± SD).

Administration

Mean contractile frequency (beat per minute, BPM)

Ca²⁺-lack
Ca²⁺-normal
Ca²⁺-rich

NS (control)
10
3.58 ± 0.79
3.57 ± 0.56
4.30 ± 0.83

AFIF, 3 μg/mL
10
3.63 ± 0.74
3.52 ± 0.53
4.37 ± 0.96

AFIF, 30 μg/mL
10
3.68 ± 0.90
3.49 ± 0.54
4.28 ± 0.81

AFIF, 300 μg/mL
10
3.57 ± 0.60
3.39 ± 0.74
4.37 ± 0.91

AFIF, 3000 μg/mL
10
3.62 ± 1.47
3.49 ± 1.09
4.69 ± 0.89

AFIF, 6000 μg/mL
10
2.16 ± 2.10
3.0 ± 0.96
4.16 ± 0.74

AFIF, 10000 μg/mL
10
0.62 ± 1.40
1.63 ± 1.30
2.75 ± 1.60

⁢ versus control.

4.4. AFIF Corrected the Enhanced Contraction Amplitude of PCSMS Induced by Acetylcholine Chloride or Neostigmine and Further Reduced the Diminished Contraction Amplitude of PCSMS Induced by Atropine

Pretreatment of acetylcholine chloride (0.35 μmol/L) and neostigmine (1 μmol/L) increased the baseline of PCSMS contraction amplitude, while atropine (1 μmol/L) decreased it. AFIF corrected the enhanced contraction of PCSMS induced by acetylcholine chloride or neostigmine and further reduced the diminished contraction amplitude of PCSMS induced by atropine (Table 4).

Table 4: Effect of AFIF on mean contraction amplitude of PCSMS after pretreatments of Ach, neostigmine, or atropine (mean ± SD).

Administration

Mean contraction amplitude (%)

Acetylcholine chloride
Neostigmine
Atropine

Pretreatment
7
197.15 ± 35.45
501.95 ± 109.74
70.89 ± 11.04

AFIF, 3 μg/mL
7
156.05 ± 17.67
422.00 ± 153.11
72.54 ± 13.81

AFIF, 30 μg/mL
7
154.02 ± 24.67
418.91 ± 128.05
70.80 ± 14.47

AFIF, 300 μg/mL
7
156.94 ± 28.02
384.70 ± 79.80
67.23 ± 17.47

AFIF, 3000 μg/mL
7
130.39 ± 19.52
299.94 ± 82.59
45.08 ± 14.38

AFIF, 6000 μg/mL
7
90.40 ± 22.20
166.69 ± 76.85
38.80 ± 19.69

AFIF, 10000 μg/mL
7
52.64 ± 23.01
76.62 ± 65.47
15.03 ± 22.90

⁢ and versus pretreatment.

4.5. AFIF Showed No Significant Effect on the Mean Contractile Frequency of PCSMS after the Pretreatment of Acetylcholine Chloride, Neostigmine, or Atropine

AFIF showed no significant inhibitory effect on the mean contractile frequency of PCSMS after pretreatment (Table 5).

Table 5: Effect of AFIF on mean contractile frequency of PCSMS after pretreatments of Ach, neostigmine, or atropine (mean ± SD).

Administration

Mean contractile frequency (beat per minute, BPM)

Acetylcholine chloride
Neostigmine
Atropine

Pretreatment
7
4.36 ± 1.51
5.26 ± 1.48
4.11 ± 0.85

AFIF, 3 μg/mL
7
4.43 ± 1.43
5.63 ± 2.24
4.11 ± 0.70

AFIF, 30 μg/mL
7
4.25 ± 1.49
5.04 ± 0.78
4.15 ± 0.67

AFIF, 300 μg/mL
7
4.23 ± 1.41
4.51 ± 0.60
4.18 ± 0.54

AFIF, 3000 μg/mL
7
4.55 ± 1.35
4.19 ± 0.39
4.28 ± 0.77

AFIF, 6000 μg/mL
7
4.24 ± 1.30
4.05 ± 0.88
3.48 ± 1.52

AFIF, 10000 μg/mL
7
3.52 ± 2.05
3.36 ± 1.59
1.37 ± 1.76

4.6. L-NAME Significantly Weakened AFIF’s Action on the Contraction Amplitude of PCSMS

Comparing to the incubation of NS (control), L-NAME (10⁻⁴ mol/L, 20 min) significantly reduced the relaxation of PCSMS induced by AFIF (Figure 5).

Figure 5: AFIF’s action on PCSMS contraction amplitude after the pretreatment of L-NAME. , versus control. Neither L-NAME nor NS significantly changed the baseline of PCSMS contraction amplitude (). However, after the incubation of L-NAME for 20 min, the effect of AFIF on PCSMS contraction amplitude was inhibited. When AFIF concentration reached 3000 μg/mL, 6000 μg/mL, and 10000 μg/mL, the mean contraction amplitude of PCSMS incubated with L-NAME was significantly higher than control ().

4.7. AFIF Significantly Increased the cGMP and PKG Levels of PCSMS

Comparing with NS incubation, AFIF (6000 μg/mL) incubation for 30 min significantly increased the cGMP and PKG levels of PCSMS measured by ELISA kits (, ) (Table 6).

Table 6: Effect of AFIF incubation on the cGMP and PKG levels of PCSMS (mean ± SD).

Incubation

cGMP (pg/mg)
PKG (nM/mg)

NS
7
1.51 ± 0.15
27.41 ± 3.53

AFIF (6000 μg/mL)
7
1.78 ± 0.12
31.60 ± 3.44

⁢ and versus control.

5. Discussion

Recently, Chinese herbals have been paid a close attention as effective treatments of functional dyspepsia [6], and some of them have been proved to regulate the contraction of gastrointestinal isolated muscle strips [10–12]. AFI, a member of the family Rutaceae, named as “Zhishi” in Chinese medicine, is used to “Po-Qi Chu-Pi (regulating qi-flowing and treating fullness)” and improve the symptoms of dyspepsia. It has been proved to promote gastric emptying process [13] and becomes a commonly used drug for the treatment of functional dyspepsia. It also has been verified by in vitro experiment that AFI decreases the contractility of isolated gastric muscle strips in rats [14]. AFIF, the major effective constituent of AFI [8], has been reported to promote gastric emptying in rats as well [9]. However, the mechanisms of AFIF’s therapeutic effect have not been clarified, and AFIF’s action on isolated gastric muscle strips has not been published yet.

Gastric emptying dysfunction is considered to be an important pathogenic factor in functional dyspepsia, which induces clinical symptoms of FD [5, 15]. However, existing prokinetic agents are not always satisfactory to promote the gastric emptying process of FD patients. Recent studies confirmed that some FD patients’ gastric contractility is hyper rather than diminished [16], and the hyper pyloric contractility can cause the dysfunction of gastric emptying [17, 18]. Some experts argued that pylorus is an independent unit of resistance in gastric emptying process [19], and relaxing pyloric sphincter muscle is a feasible way to regulate gastrointestinal motility and improve FD symptoms [20].

As we know, the intracellular Ca²⁺ homeostasis is the basis for maintaining normal contraction and relaxation of smooth muscle. Extracellular Ca²⁺ can be charged or discharged by muscle cells through the cell membrane, leading to the increase or decrease of intracellular Ca²⁺ concentration, which causes the contraction or relaxation of smooth muscle. It is well known that nitric oxide (NO) is one of the most important regulatory factors in alimentary tract which adjust the gastrointestinal motility. It activates intracellular guanylate cyclase to catalyze guanosine triphosphate (GTP) and generate cGMP, which further activates PKG to prevent the influx of extracellular Ca²⁺ and induces a decrease of intracellular Ca²⁺ concentration, causing smooth muscle relaxation. The reported study also demonstrated that NOS decreases Ca²⁺ concentration in muscle cells by upregulating cGMP level [21].

Previous animal experiments have proved that AFIF upregulates NO concentration in serum [22] and NO can accelerate gastric emptying by inhibiting the contraction of pylorus [23]. According to a recent study [24], Poncirus fructus, another member of the family Rutaceae which is closely related to AFI, can reduce the smooth muscle contraction of experiment animals, and this action can be significantly inhibited by L-NAME.

In this study, AFIF did not show any significant effect on the contraction of ALSMS, but it showed a concentration-dependent inhibitory action on the spontaneous contraction of PCSMS. AFIF’s inhibitory action on the mean contraction amplitude of PCSMS was significant when its concentration reached 3000 μg/mL, 6000 μg/mL, and 10000 μg/mL. And its effect on the contractile frequency of PCSMS was significant only when its concentration reached 10000 μg/mL. In another experiment, we used Ach and neostigmine to induce the enhancing of PCSMS contraction which can partly simulate the abnormally enhanced contraction of pylorus. In this experiment, AFIF effectively corrected the pathological condition of PCSMS contraction. Our research also showed that AFIF’s action was negatively correlated with Ca²⁺ concentration in the bath, which demonstrated that the diastolic effect of AFIF on PCSMS is likely to be related to inhibiting extracellular Ca²⁺ influx and downregulating intracellular Ca²⁺ concentration. Our results also showed that L-NAME significantly weakened AFIF’s diastolic effect on PCSMS contraction. And AFIF (6000 μg/mL) incubation increased the levels of cGMP and PKG in PCSMS significantly. These results demonstrated that the diastolic effect of AFIF on PCSMS is probably achieved by activating NOS and associated with upregulating cGMP and PKG levels. However, the specific composition of AFIF working in this process still remains to be further studied.

6. Conclusions

As the major effective constituent of AFI, AFIF has a diastolic effect on PCSMS. This effect of AFIF is closely related to activating NOS, upregulating cGMP and PKG levels, and downregulating intracellular Ca²⁺ concentration of smooth muscle. Our study may partly elucidate the mechanism of AFIF’s action in the treatment of FD and provide some ideas for the complementary and alternative therapies.

Competing Interests

The authors declare that they have no competing interests.

Acknowledgments

This study was supported by grants from the following: (1) the Project of Beijing Municipal Science & Technology Commission (no. Z131100002513012); (2) the Clinical Medicine Development Project of Beijing Municipal Administration of Hospitals (no. ZYLX201411); (3) the National Natural Science Foundation of China (no. 81503514).

References

J. Tack, N. J. Talley, M. Camilleri et al., “Functional gastroduodenal disorders,” Gastroenterology, vol. 130, no. 5, pp. 1466–1479, 2006.

H. B. El-Serag and N. J. Talley, “The prevalence and clinical course of functional dyspepsia,” Alimentary Pharmacology & Therapeutics, vol. 19, no. 6, pp. 643–654, 2004.

L. Van Oudenhove, J. Vandenberghe, R. Vos, L. Holvoet, K. Demyttenaere, and J. Tack, “Risk factors for impaired health-related quality of life in functional dyspepsia,” Alimentary Pharmacology and Therapeutics, vol. 33, no. 2, pp. 261–274, 2011.

R. A. Brook, N. L. Kleinman, S. R. Choung et al., “Functional dyspepsia impacts absenteeism and direct and indirect costs,” Clinical Gastroenterology and Hepatology, vol. 8, no. 6, pp. 498–503, 2010.

M. Camilleri, “Functional dyspepsia: mechanisms of symptom generation and appropriate management of patients,” Gastroenterology Clinics of North America, vol. 36, no. 3, pp. 649–664, 2007.

C. Wang, M. Zhu, W. Xia, W. Jiang, and Y. Li, “Meta-analysis of Traditional Chinese Medicine in treating functional dyspepsia of liver-stomach disharmony syndrome,” Journal of Traditional Chinese Medicine, vol. 32, no. 4, pp. 515–522, 2012.

H. Wu, Z. Jing, X. Tang et al., “To compare the efficacy of two kinds of Zhizhu pills in the treatment of functional dyspepsia of spleen-deficiency and qi-stagnation syndrome: a randomized group sequential comparative trial,” BMC Gastroenterology, vol. 11, article 81, 2011.

Y.-S. Fang, D.-M. Shan, J.-W. Liu et al., “Effect of constituents from Fructus Aurantii Immaturus and Radix Paeoniae Alba on gastrointestinal movement,” Planta Medica, vol. 75, no. 1, pp. 24–31, 2009.

A. Huang, Y. Chi, Y. Zeng, and L. Lu, “Influence of fructus aurantii immaturus flavonoids on gastrointestinal motility in rats with functional dyspepsia,” Traditional Chinese Drug Research & Clinical Pharmacology, vol. 23, pp. 612–615, 2012.

T.-Z. Zheng, W. Li, S.-Y. Qu, Y.-M. Ma, Y.-H. Ding, and Y.-L. Wei, “Effects of Dangshen on isolated gastric muscle strips in rats,” World Journal of Gastroenterology, vol. 4, no. 1–6, pp. 354–356, 1998.

C. Yang, S.-S. Zhang, X.-L. Li, Z.-F. Wang, and L.-Q. Zhao, “Inhibitory effect of TongXie-YaoFang formula on colonic contraction in rats,” World Journal of Gastroenterology, vol. 21, no. 10, pp. 2912–2917, 2015.

M. Yu, Y.-L. Luo, J.-W. Zheng et al., “Effects of rhubarb on isolated gastric muscle strips of guinea pigs,” World Journal of Gastroenterology, vol. 11, no. 17, pp. 2670–2673, 2005.

Z. H. Huang, D. Z. Yang, and Y. Q. Wei, “Effect of atropine on the enhancing action of Fructus Aurantii Immaturus on the myoelectric activity of small intestine in dogs,” Chinese Journal of Integrated Traditional and Western Medicine, vol. 16, no. 5, pp. 292–294, 1996.

Z. Tianzhen, L. Wei, Q. Songyi, D. Yonghui, and W. Yuling, “Action of traditional Chinese medicines of Zhishi and Baizhu on contractile activity of isolated gastric muscular strips in rats,” Journal of Gansu Sciences, vol. 10, pp. 66–68, 1998.

H. Miwa, “Why dyspepsia can occur without organic disease: pathogenesis and management of functional dyspepsia,” Journal of Gastroenterology, vol. 47, no. 8, pp. 862–871, 2012.

A. E. Bharucha, A. Manduca, D. S. Lake et al., “Gastric motor disturbances in patients with idiopathic rapid gastric emptying,” Neurogastroenterology & Motility, vol. 23, no. 7, pp. 617–e252, 2011.

C. A. Paterson, M. Anvari, G. Tougas, and J. D. Huizinga, “Determinants of occurrence and volume of transpyloric flow during gastric emptying of liquids in dogs: importance of vagal input,” Digestive Diseases and Sciences, vol. 45, no. 8, pp. 1509–1516, 2000.

Giulir, T. R. Demester, and R. Leven, “Surgical complication and reasons for failure,” in Cancer of the Esophagus, pp. 199–208, Grune & Stratratton Inc, Orlando, Fla, USA, 1985.

F. E. Lüdtke, E. Lammel, K. Mandrek, H. J. Peiper, and K. Golenhofen, “Myogenic basis of motility in the pyloric region of human and canine stomachs,” Digestive Diseases, vol. 9, no. 6, pp. 414–431, 1991.

D. Ramkumar and K. S. Schulze, “The pylorus,” Neurogastroenterology and Motility, vol. 17, no. 1, pp. 22–30, 2005.

R. Wenhai, W. Xinzeng, W. Zhenghua, L. Zhongchang, and Z. Xia, “Effect of iron deficiency on gastric emptying function of rats and its mechanism,” Journal of the Fourth Military Medical University, vol. 20, pp. 756–758, 1999.

C. Jiayi, Study on PK and PD in Irritable Bowel Syndrome with Syndrome of Liver Invading the Spleen of Extract from Citrus Aurantium, Guangzhou University of Chinese Medicine, Guangzhou, China, 2014.

M. Anvari, C. A. Paterson, and E. E. Daniel, “Role of nitric oxide mechanisms in control of pyloric motility and transpyloric flow of liquids in conscious dogs,” Digestive Diseases and Sciences, vol. 43, no. 3, pp. 506–512, 1998.

D. Yu, J. Jun, T. Kim, D. Suh, D. Youn, and T. Kim, “The relaxing effect of Poncirus fructus and its flavonoid content on porcine coronary artery,” Laboratory Animal Research, vol. 31, no. 1, pp. 33–39, 2015.